1 month ago
Trump Proposes Tariffs on Generic Drugs
President Trump wants to put high taxes on generic drugs coming from other countries, starting in 2028.
This is to make companies move their factories to the US.
India sends a lot of these drugs to the US, so this could hurt Indian companies.
It might also make drugs more expensive for Americans, which could be bad for their health care system.
Trump thinks this will help American jobs, but others say it might not work because making drugs cheaply in the US is hard.
President Trump plans to impose steep tariffs on imported generic drugs starting in 2028.
The tariffs aim to encourage Indian pharma companies to move production to the US.
India exports $213 billion worth of generic drugs to the US annually.
The tariffs could drive up public healthcare costs in America.
Top 5 US pharma companies have a combined revenue of $350 billion and market cap of $2,791 billion.
- Who
- US President Donald Trump
- What
- Proposed steep tariffs on imported generic drugs
- Where
- United States
- When
- Implementation starts in 2028
- Why
- To onshore production of generic drugs
Pro-Tariff Perspective
Anti-Tariff Perspective
Impact on Indian Pharma Sector
Pro-Tariff Perspective
The tariffs will encourage Indian pharma companies to move production to the US, boosting local manufacturing.
Anti-Tariff Perspective
The tariffs will negatively impact the profitability of the Indian pharma sector, which is a major exporter of generic drugs to the US.
Public Healthcare Costs
Pro-Tariff Perspective
The tariffs will drive up public healthcare costs in America, impacting government budgets and increasing the fiscal deficit.
Anti-Tariff Perspective
The tariffs will make generic drugs more expensive, but this is a necessary step to protect American jobs and industries.
Key facts
- Tariff Implementation
- None till 2028, 100% from August 1, 2028, to July 31, 2029, and 200% from August 1, 2029.
- Indian Pharma Exports to US
- $213 billion worth of generic drugs.
- Top 5 US Pharma Companies Revenue
- $350 billion.
- Top 5 US Pharma Companies Market Cap
- $2,791 billion.
- Top 5 Indian Pharma Companies Valuation
- $120 billion.
Quotes
Chandrachur Datta
Partner at Vector Consulting Group, trade analyst
“The zero‑tariff window through 2028 gives the industry a meaningful runway, and we see this as time we can use productively — to keep strengthening our position across multiple markets rather than relying on any single one.”
businesstoday.in
“Existing on‑shore capacities of most large Indian manufacturers are not sufficient to absorb the load completely, so companies will need a clear framework to decide which products should be manufactured in such capacities.”
businesstoday.in
Sources
Related news
Bengaluru Engineers Develop Affordable AI PC KEO
Volvo ES90 And EX90 Electric Flagships Launch In India
Volvo EX90 and ES90 India Launch Set for October 12
Jefferies sees 40% upside in Kalyan Jewellers shares
Joyalukkas Launches Primora Diamond Collection Worldwide
Amazon Great Freedom Sale 2026 Smartphone Discounts Revealed
India's Pharma Sector Shifts to Innovation
